Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity - PubMed (original) (raw)
Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity
Ozer Arican et al. Mediators Inflamm. 2005.
Abstract
Recent progress in the understanding of psoriasis has shown that the regulation of local and systemic cytokines plays an important role in its pathogenesis. The most often used psoriasis score is the psoriasis area and severity index (PASI). A simple laboratory test from a blood sample would be an attractive, patient-independent, and observer-independent marker of disease severity. To this end, we evaluated the association of serum levels of some proinflammatory cytokines in vivo and their correlation with severity of psoriasis. The serum levels of cytokines levels were determined with the use of the ELISA method. All mean values except IL-17 levels of patients were significantly higher than those of controls. There was a significant correlation between serum levels of IFN-gamma, IL-12, IL-17, and IL-18, and severity of the disease. Psoriasis can be described as a T-cell-mediated disease, with a complex role for a variety of cytokines, which has led to the development of new immunomodulatory therapies. In this study, serum TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, and IL-18 levels were significantly higher in active psoriatic patients than in controls. Furthermore, high levels of IFN-gamma, IL-12, and IL-18 correlated with the clinical severity and activity of psoriasis, and those measurements of serum levels of these cytokines may be objective parameters for the disease severity.
Figures
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Figure 1
(a) IFN-γ, (b) TNF-α, (c) IL-6, (d) IL-8, (e) IL-12, and (f) IL-18 serum levels of psoriatic patients and controls in box plot graphics (○: outliers).
Similar articles
- Serum levels of interleukin-8, tumor necrosis factor-α and γ-interferon in Egyptian psoriatic patients and correlation with disease severity.
Abdel-Hamid MF, Aly DG, Saad NE, Emam HM, Ayoub DF. Abdel-Hamid MF, et al. J Dermatol. 2011 May;38(5):442-6. doi: 10.1111/j.1346-8138.2010.01018.x. Epub 2010 Sep 20. J Dermatol. 2011. PMID: 21352285 - Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity.
Jacob SE, Nassiri M, Kerdel FA, Vincek V. Jacob SE, et al. Mediators Inflamm. 2003 Oct;12(5):309-13. doi: 10.1080/09629350310001619753. Mediators Inflamm. 2003. PMID: 14760939 Free PMC article. - Plasma concentrations of IFN-gamma and TNF-alpha in psoriatic patients before and after local treatment with dithranol ointment.
Chodorowska G. Chodorowska G. J Eur Acad Dermatol Venereol. 1998 Mar;10(2):147-51. J Eur Acad Dermatol Venereol. 1998. PMID: 9553912 Clinical Trial. - [Metabolic disorders in patients with psoriasis].
Sikora-Grabka E, Adamczak M, Wiecek A. Sikora-Grabka E, et al. Przegl Lek. 2011;68(12):1193-8. Przegl Lek. 2011. PMID: 22519279 Review. Polish. - Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis.
Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Dowlatshahi EA, et al. Br J Dermatol. 2013 Aug;169(2):266-82. doi: 10.1111/bjd.12355. Br J Dermatol. 2013. PMID: 23550658 Review.
Cited by
- The Impact of Disease Severity on the Serum Levels of Significant Neutrophil Extracellular Trap (NET) Proteins in Patients with Psoriasis.
Czerwińska J, Owczarczyk-Saczonek A. Czerwińska J, et al. Int J Mol Sci. 2024 Oct 3;25(19):10671. doi: 10.3390/ijms251910671. Int J Mol Sci. 2024. PMID: 39409000 Free PMC article. - Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021.
Meulewaeter E, Eylenbosch A, Verhaeghe E, Soenen R, Lambert J. Meulewaeter E, et al. Dermatol Ther (Heidelb). 2024 Oct;14(10):2889-2903. doi: 10.1007/s13555-024-01277-y. Epub 2024 Oct 4. Dermatol Ther (Heidelb). 2024. PMID: 39365432 Free PMC article. - A Multiplexed Quantitative Proteomics Approach to the Human Plasma Protein Signature.
Núñez E, Gómez-Serrano M, Calvo E, Bonzon-Kulichenko E, Trevisan-Herraz M, Rodríguez JM, García-Marqués F, Magni R, Lara-Pezzi E, Martín-Ventura JL, Camafeita E, Vázquez J. Núñez E, et al. Biomedicines. 2024 Sep 18;12(9):2118. doi: 10.3390/biomedicines12092118. Biomedicines. 2024. PMID: 39335631 Free PMC article. - A Narrative Review of the IL-18 and IL-37 Implications in the Pathogenesis of Atopic Dermatitis and Psoriasis: Prospective Treatment Targets.
Rusiñol L, Puig L. Rusiñol L, et al. Int J Mol Sci. 2024 Aug 2;25(15):8437. doi: 10.3390/ijms25158437. Int J Mol Sci. 2024. PMID: 39126010 Free PMC article. Review. - Biomarkers in Psoriasis: The Future of Personalised Treatment.
Kar BR, Sathishkumar D, Tahiliani S, Parthasarathi A, Neema S, Ganguly S, Venkatachalam K, Parasramani SG, Komeravelli H, Thomas J. Kar BR, et al. Indian J Dermatol. 2024 May-Jun;69(3):256-263. doi: 10.4103/ijd.ijd_167_24. Epub 2024 Jun 26. Indian J Dermatol. 2024. PMID: 39119310 Free PMC article.
References
- Lowes MA, Lew W, Krueger JG. Current concepts in the immunopathogenesis of psoriasis. Dermatol Clin. 2004;22(4):349–369. - PubMed
- Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today. 1999;20(1):40–46. - PubMed
- Griffiths CEM. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):1–5. - PubMed
- Chamian F, Krueger JG. Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol. 2004;16(4):331–337. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous